Background: The role of telemedicine in the management of patients with chronic heart failure (HF) has not been fully elucidated. We hypothesized that multidisciplinary comprehensive HF care could achieve better results when it is delivered using telemedicine. Methods and results: In this study, 178 eligible patients with HF were randomized to either structured follow-up on the basis of face-to-face encounters (control group, 97 patients) or delivering health care using telemedicine (81 patients). Telemedicine included daily signs and symptoms based on telemonitoring and structured follow-up by means of video or audio-conference. The primary end-point was non-fatal HF events after six months of follow-up. The median age of the patients was 77 years, 41% were female, and 25% were frail patients. The hazard ratio for the primary end-point was 0.35 (95% confidence interval (CI), 0.20-0.59; p-value < 0.001) in favour of telemedicine. HF readmission (hazard ratio 0.39 (0.19-0.77); p-value¼0.007) and cardiovascular readmission (hazard ratio 0.43 (0.23-0.80); p-value¼0.008) were also reduced in the telemedicine group. Mortality was similar in both groups (telemedicine: 6.2% vs control: 12.4%, p-value > 0.05). The telemedicine group experienced a significant mean net reduction in direct hospital costs of E3546 per patient per six months of follow-up. Conclusions: Among patients managed in the setting of a comprehensive HF programme, the addition of telemedicine may result in better outcomes and reduction of costs.
Introduction
Randomized controlled trials 1 and recent pragmatic studies that have explored real-life implementations of heart failure (HF) management programmes 2 have shown that organizing health care in accordance with the principles of the chronic care model 3 improves adherence to prescription of evidence-based therapy and clinical outcomes. 1, 2, 4 Much of the success of these programmes is based, primarily, on delivering a planned, structured, nurse-based follow-up to patients and, secondly, on encouraging patient self-monitoring to promote early detection and treatment of decompensation in order to avoid readmissions and improve survival. 2, 4 In this regard, there has been a growing interest in implementing strategies for early detection of deterioration in these patients by taking advantage of telemedicine. Although this concept is very reasonable, well designed and adequately powered studies have failed to prove that a telemonitoring-based follow up strategy provides additional benefits to the usual care in chronic HF (CHF). 5, 6 These findings are in conflict with data coming from previous studies 7, 8 showing that a telemedicine-based follow-up strategy was feasible and may be more efficient in reducing CHF-related clinical events compared to usual care. However, the efficacy of the combination of telemonitoring and comprehensive multidisciplinary care compared to comprehensive multidisciplinary care alone is a more controversial issue. In the Trans-European Network-Home-Care Management System (TEN-HMS) study, 7 the primary end-point was not significantly different between remote structured follow-up with or without telemonitoring though the combined strategy appeared to be marginally better in some secondary end-points. Moreover, in a recently reported trial conducted in Finland, the addition of telemonitoring to comprehensive management of HF did not improve clinical outcomes and was associated with an increase in the use of healthcare resources. 9 Thus, the exact role and the potential benefits (if any) of adding a combination of remote monitoring and teleintervention using telemedicine services on top of delivery of care within multidisciplinary HF programmes needs further evaluation.
Thus, the aim of our study was to evaluate the impact of adding telemedicine to a multidisciplinary HF programme.
Methods
The insuficie`ncia Cardıáca Optimitzacio´Remota (iCOR; Heart Failure Remote Optimization) trial was a singlecentre, randomized, open-label study designed to evaluate the efficacy of the addition of telemedicine (telemonitorization and teleintervention using videoconference) to an existing specialized, multidisciplinary, nurse-based, hospitalprimary care integrated HF programme for high-risk patients with CHF. The organizational characteristics of the programme and the impact in health outcomes resulting from its implementation have been previously published. 2 In this study we aimed to compare the strategy of providing nurse-based structured follow-up to high-risk CHF patients through planned contacts between health care providers and patients and/or caregivers in the basis of face-to-face on-site encounters (usual care in our HF programme) or provide the planned care using telemedicine with the combination of remote daily monitoring of signs and symptoms of HF (telemonitoring) and delivery of structured nursebased follow-up health care using videoconference (teleintervention). The main hypothesis of this study was that adding telemedicine to an existing HF programme would be associated with a reduction in the number of non-fatal HF events in high-risk patients with CHF. As a secondary hypothesis we assumed that adding telemedicine would translate into a reduction in health care resource utilization and subsequently in health care costs.
Study design and oversight
Patients were recruited during 23 months (December 2010-October 2012) and followed for a fixed period of six months. The study protocol was approved by the institutional review board of the Hospital del Mar Research Institute (IMIM). All patients provided written informed consent. The study was registered on the website www.ClinicalTrials.gov (unique identifier: NCT01495078).
Study population, eligibility and recruitment
Inclusion criteria for this study were: over 18 years of age, clinical diagnosis of CHF according to the presence for >3 months of typical signs and symptoms of HF and the evidence of underlying structural heart disease or current hospital admission for acute decompensated HF needing intravenous diuretics. The study included HF patients with either reduced ejection fraction (HFrEF) or preserved (HFpEF) ejection fraction. HFpEF was defined as left ventricular ejection fraction (LVEF) 5 45%. Major exclusion criteria were moderate or severe cognitive impairment without a caregiver, lack of social support, institutionalized patients, life expectancy less than one year (excluding HF), planned end-of-life care, planned cardiac invasive procedures, planned haemodialysis, death before hospital discharge and inability or unwillingness to give informed consent. Before discharge from the hospital and thus, before final inclusion in the protocol, patients had to be stable, without signs of fluid overload or low-cardiac output and receiving oral standard medication for CHF.
Randomization
Eligible patients that signed the informed consent were randomized in a 1:1 ratio to usual care (HF programme (HFP)) or intervention group (HFPþtelemedicine (HFPþT)). Randomization was stratified according the presence or absence of frailty to ensure balanced assignment of frail patients to each group. This was achieved generating two different randomization lists with no specific permuted blocks: one for non-frail patients and one for frail patients. According to our HF programme protocols, frailty was defined according to the following criteria: age 5 90 years or age 85-89 needing caregiver or moderate to severe dependency for basic activities of daily living (Barthel Index < 90) at any age or moderate to severe cognitive impairment according to the Pfeiffer test at any age. Allocation of patients was performed and communicated to the investigators and attending health care professionals by independent administrative staff following the computer-generated randomization scheme.
Overview of the home Tele-HealthCare (THC) platform
The home THC platform is a comprehensive solution for the care and monitoring of chronic patients, modelled and tested in patients with CHF that enables the provision of multichannel service and patient tracking through patient monitoring of biometric data (weight, heart rate and blood pressure), symptoms reporting (seven questions to capture worsening symptoms of the cardiac condition, mainly worsening heart failure, and one question to capture general worsening), generation and management of warning alarms (biometrics out of range) and alerts (information related to the function of the household devices). This was the gateway for receiving information from household devices using Bluetooth and sending patient's information to the clinical workstation using 3G technology. Both, home touchscreen computer and 3G access were provided by the telemedicine service. In all cases, 3G connectivity allowed transmission of biometrics and performing videoconferences with good quality. In the current version, the patients' interface was installed in a tablet with 3G connectivity provided by the telemedicine service. The platform allows promoting self-care and selfefficacy of patients by giving them up-to-date information about individual evolution of patient's biometrics and issuing educational videos through this interface.
The development of the telemedicine platform was conducted by telecommunication engineers of Telefonica Soluciones S.A. in collaboration with researchers of the Hospital del Mar Medical Research Institute (IMIM) and based upon a Research and Innovation Agreement signed between both institutions. The THC platform is currently a commercial service of Telefonica Soluciones S.A. and this company has full ownership of the product.
HF programme with or without telemedicine: differences between the two management strategies
The study was undertaken in an already existing specialized, comprehensive, multidisciplinary, nurse-based, hospital-primary care integrated HF programme for high-risk patients with CHF developed in an integrated health care area. 2 Patients assigned to the telemedicine group were followed and treated in the same manner as patients assigned to the HFP group in terms of number of scheduled visits and content of the intervention since both strategies shared the same protocols and algorithms. Each individual patient was contacted according to the assigned strategy: in the HFP group, the appointments were on-site face-to-face visits either at home (frail patients) or at the HF outpatient clinic (non-frail). In the HFPþT group, these encounters were virtual contacts by videoconference, audio-conference or telephone between the health care professional and the patient and caregiver (at home). All patients in the HFPþT group performed daily automated telemonitoring of biometrics and symptoms using the home THC platform. Patients in this group were instructed to obtain bio-measures once a day, preferably after waking up, to be transferred to the clinical workstation. Telemedicine HF nurses reviewed alarms and alerts from the system everyday (working days and office hours). In the HFP group, as we mentioned, patients were instructed to perform these same determinations, record them and contact the nurse when these were out of range. In both strategies, in case of suspected decompensation, nurses could promote diuretic dose adjustments following specific protocols and algorithms and/or obtain the immediate support of a heart failure specialist. After hospital discharge, patients in the HFPþT group received an early home visit (<7 days) by the telemedicine HF nurse to set up the home telemedicine platform and train patients and caregivers in its use. Similarly, patients in the HFP group received an early visit (<7 days) either at home (in frail patients by the primary care case manager) or at the HF outpatient clinic (in non-frail by a HF nurse). At the end of followup, continuity of care was provided by the primary care team including a case manager, primary care doctor and nurse and the primary care cardiologist.
Data collection
Medical history, relevant clinical and demographic information, physical examination, laboratory tests and functional evaluation was obtained at baseline. All patients underwent a complete psychosocial evaluation using validated questionnaires. [10] [11] [12] [13] [14] Self-efficacy (European Self-Care Behavior Scale) 13 and health-related quality of life (Minnesota Living with Heart Failure Questionnaire) 14 were also measured at the end of follow-up.
Follow-up and evaluation of end-points
All patients were evaluated at hospital discharge and for six months thereafter according to the above-mentioned intervention strategies. Information on end-points was obtained from the hospital and primary care electronic medical records or by direct interview of patients or caregivers. The primary end-point and other secondary endpoints including readmissions or death were adjudicated by an independent end-point committee whose members were unaware of group assignment.
Non-fatal HF event was the primary end-point of our study. This end-point has been used as a component of the primary end-point in a previous randomised controlled trial (RCT). 15 For the purpose of this study, a non-fatal HF event was defined as a new episode of worsening of symptoms and signs consistent with acute decompensated HF requiring intravenous decongestive therapy (intravenous furosemide) according to the treating physician either on an outpatient basis (day-case HF hospital) or in the emergency department (<24 h) or requiring unplanned hospital admission (>24 h) or complicating the course of a non-HF hospital admission (i.e. bronchial infection).
Secondary end-points were all-cause and cardiovascular mortality, unplanned readmissions (all-cause, HF and cardiovascular), changes in patient-centred outcomes (self-efficacy and quality of life) and health care costs.
Methodology of health care costs evaluation
The period of cost evaluation in each patient was comprised between the day post-discharge and the day of the end-of-study visit (end of planned follow-up or day of death). Cost calculation included pharmacy, complementary examinations, referrals, outpatient care, emergency room visits, readmissions and procedures. The methodology of the home THC platform project was used for the cost calculations. The hospital uses a cost accounting system based on full-costing allocation that allows for assessing direct costs derived from clinical activity. In the present study, cost estimation was based on a full-cost accounting system and on the criteria of clinical activity-based costing methods to obtain the highest sensitivity in the assessment of variability in clinical activity. Moreover, this system ensures that the hospital's total costs are distributed among the patients. Allocation was based on directly assigning the cost of the following services to the patient: laboratory, pharmacy, radiology, nuclear medicine, pathology and prosthetics. The information systems contain exhaustive data on human resources and their activity, i.e. storage, admissions planning, ambulatory and emergency care, operating rooms, diagnostic and complementary tests, and intrahospital consultations (specialist referrals). This information creates and automatically updates the cost drivers for overheads. This method has been used in health care cost evaluation by our group. 16 For this particular analysis, direct costs were also grouped in three categories: cost of hospitalization (cost of medical and nursing staff, pharmacy, invasive procedures, emergency room visits and associated costs that occurred during admissions), cost of diagnostics procedures (non-invasive diagnostic procedures including radiology, nuclear testing, laboratory, referrals to other specialists and associated costs) and cost of ambulatory care (including costs of medical and nursing staff during ambulatory follow-up, use of the day-case hospital, treatments administered in the day-case hospital, the costs of the telemedicine service and associated costs of ambulatory care).
Statistical analyses
Demographic and other background data were summarized with basic descriptive statistics in the total cohort and according to the treatment group. For quantitative variables, the arithmetic mean (AEstandard deviation) or geometric means (95% confidence intervals (CIs)) were calculated as appropriate, and p-values were derived from a two-sample t-test (non-parametric tests were used for skewed data). For qualitative variables, percentages were calculated and p-values were derived using 2 tests. Primary and secondary end-points were evaluated using Cox proportional-hazards model with group assignment as the only covariate. We also conducted sensitivity analyses including (a) adjustment for relevant baseline covariates (age, gender, New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), criteria of frailty, educational level and baseline self-efficacy) and (b) including all patients that were screened and randomized. Unitary direct hospital costs obtained by hospital cost accountability methods were compared between treatment groups using non-parametric tests (Wald-Wolfowitz runs test and Kolmogorov-Smirnov z test for two independent samples). Changes in self-efficacy were analysed using Wilcoxon rank tests for paired variables. To evaluate accuracy of the analyses we undertook internal validation using re-sampling methods that included additional bootstrap analysis (1000 cycles) of each bivariate and multivariate model.
All statistical tests and confidence intervals were constructed with a type I error (alpha) level of 5%, and p-values 4 0.05 were considered statistically significant. SPSS version 18.0 (IBM, Armonk, New York, USA) was used for statistical analyses. Figure 1 reports the flow of patients in the process of screening. During the recruiting period of the study, 358 consecutive patients were screened. Of these, 133 were not eligible and 34 declined to participate. The remaining 188 patients were initially enrolled and randomized before discharge: 88 were assigned to the telemedicine group and 100 to the HFP group. At discharge, seven patients in the HFPþT group and three patients in the HFP group did not fulfil eligibility criteria and were finally excluded from the primary analysis. Thus the final study group consisted of 178 patients. Excluded patients, compared to those included, did not differ in terms of age, gender, LVEF, NYHA or pre-discharge NT-proBNP levels (all pvalues > 0.05).
Results

Baseline characteristics
Both groups were well balanced in terms of baseline demographic and clinical factors (Table 1 ). There were no statistically significant differences between both arms in any of clinical or demographic variables evaluated at baseline. Median age of patients was 77 years (ranged from 40-92 years), and a high proportion of patients had HFpEF. The presence of comorbidities was high in this cohort of patients. There were no differences between both groups in terms of psychosocial characteristics (Table 1) including self-efficacy and level of studies. One-quarter of the patients fulfilled frailty criteria and thus home-based care was planned for them. In these frail patients, 83% had a competent caregiver available (78% in the HFPþT group vs 87% in the HFP group, p-value > 0.05). In the control group, care was delivered at home in the 25 patients that fulfilled frailty criteria (26%). In the remaining 72 patients of the control group, appointments were scheduled in our outpatient HF clinic. In the telemedicine group, 19 patients (24%) fulfilled frailty criteria and the remaining 62 patients of this group were not frail. In this latter group, all scheduled appointments were conducted using telemedicine. Quality of life assessed using the Minnesota Living with Heart failure Questionnaire was poor at baseline (median score of 55 points) and was not different between both groups (p-value > 0.05). We prospectively evaluated how the patients would cope with the use of telecommunication technology as an instrument for their follow-up. At baseline, 61% of patients in the total cohort anticipated that they would have a high level of difficulty regarding the use of technological devices while 29% considered that this difficulty would be low. Despite this, the level of adherence to the use of the devices in the telemedicine group was very high with a proportion of missed biometric daily transmissions <1% of the planned and expected number of daily transmissions. Additionally, after six weeks of follow-up patients were asked to rate their level of satisfaction with the telemedicine system from 0 (not satisfied at all) to 10 (highest satisfaction). Regarding this, the mean score was 9.6 AE 0.9 points, 79% rating 10 and 96% rating > 7 points.
Primary outcome
A total of 121 primary events occurred during the study period, 27 in the HFPþT group and 94 in the HFP group.
In the telemedicine group, two non-fatal HF events were resolved in our HF-day case hospital, five were treated at the emergency department (<24 h) and 15 required hospital admission. The remaining five non-fatal HF events occurred in the course of a non-HF hospitalization complicated with worsening HF. In the usual care group, 31 non-fatal HF events were resolved in our HF-day case hospital, 12 were treated at the emergency department (<24 h) and 40 required hospital admission. The remaining 11 non-fatal HF events occurred in the course of a non-HF hospitalization complicated with worsening HF. The mean number of non-fatal HF events was significantly lower in the HFPþT group compared to the HFP group (0.33 AE 0.7 vs 0.97 AE 1.2, p-value < 0.001, respectively). The primary end-point (Figure 2(a) ) occurred at least once in 18 patients (22%) in the HFPþT group and in 51 (53%) of the HFP group (p-value < 0.001). The rate of patients with multiple non-fatal HF events was also lower in the HFPþT group compared with the HFP group (p-value < 0.001). The hazard ratio for the primary end-point (Table 2, Figure 2(b) ) was 0.35 Anaemia was defined using the World Health Organization criteria (haemoglobin level < 12 g/dl in women and < 13 g/dl in men). d Self-efficacy was evaluated using the European Self-Care Behaviour Scale (score range 12-60, with higher scores indicating worse self-efficacy).
(95% CI, 0.20-0.59) in favour of the HFPþT group. In adjusted models the results were comparable with a hazard ratio of 0.33 (95% CI, 0.20-0.57, p-value < 0.001).
Inclusion of the patients that were screened and randomized but did not met final inclusion criteria (Figure 1) showed similar results (p-value < 0.001). According to an absolute risk reduction of 31% in the rate of the primary end-point, the number of patients necessary to treat (NNT) to prevent a non-fatal HF event would be three. 
Secondary outcomes
All-cause readmission ( Table 3 ) occurred in 20 patients (25%) of the HFPþT group and in 45 patients (46%) in the control group (p-value¼0.003). The incidence per 100 patients-years at risk and the hazard ratio for this secondary end-point were also in favour of the group that received telemedicine ( Table 2 ). The positive effects in all-cause hospitalization obtained in the HFPþT group were mainly driven by the prevention of cardiovascular and particularly HF related-hospitalizations (Tables 2  and 3 and Figure 3 ). In this regard, the HF and cardiovascular readmission rate experienced a 19% and 20% absolute reduction respectively. Accordingly, the NNT to prevent one of these events would be five for both. In this direction, the mean number of days in hospital was significantly reduced in the HFPþT group for all cause, HF and cardiovascular readmissions ( Table 3 ). In those patients hospitalized, mean duration of each hospitalization tended to be shorter in the telemedicine group. In adjusted models, the results were similar (data not shown). No significant differences were seen between the two groups with respect to mortality. All-cause death occurred in five patients (6.2%) in the HFPþT group and in 12 patients (12.4%) in the HFP group. As expected, deaths were mostly due to cardiovascular causes and occurred in four patients (4.9%) of the HFPþT group and in 10 patients (10.3%) in the HFP group. The combined end-point of all-cause death or HFreadmission occurred in 12 patients (15%) in the HFPþT and in 33 patients (34%) in the HFP group (NNT¼5, p ¼ 0.003).
Patient-centred outcomes
Most surviving patients experienced an improvement in self-perceived health status: 113 patients (80%) out of the 142 surviving patients with available scores without imputation at the end of the study reported an improvement >5 points in the health-related quality of life questionnaire, considered to be the minimal clinically important change. 14 Such an improvement was reported in 63 patients (88%) in the telemedicine group and in 50 patients (71%) in the usual care group (p-value¼0.02). Compared to baseline, self-efficacy evaluated with the European Self-Care Behaviour Scale improved in all patients (p-value < 0.05 in both groups). Interestingly, the proportion of patients scoring 12 points (lowest score in this questionnaire indicating the best level of self-care) at the end of the study, tended to be higher in the HFPþT group compared to the HFP group (43% vs 27%, respectively) although the difference was marginally non-significant (p-value ¼ 0.055).
Subgroup analyses
Subgroup analyses for the primary end-point ( Figure 4) showed consistent results across all pre-specified subgroups according to age, gender and other important clinical and psychosocial variables. The benefits were similar in patients with both HFrEF and HFpEF. Interestingly, there were no significant interactions between the main treatment effect and the presence of depressive symptoms, education level or the presence of frailty. 
System-centred outcomes
Unitary direct hospital costs including the costs of implementing the telemedicine service were evaluated using our cost accounting system based on full-costing allocation. The total health care costs of the whole cohort were E1,124,245. The costs of re-hospitalization accounted for two thirds (67%) of the total costs. The net savings in favour of the telemedicine group were E3546 per patient per six months of follow-up. The total health care cost experienced ( Figure 5(a) ) a relative reduction of 45% in the telemedicine group (p < 0.001) when compared to the control group. This reduction was mainly driven by a significant reduction in costs of hospitalization (63% relative reduction, p < 0.001) and a 59% relative reduction in diagnostic procedures (p ¼ 0.010) in the telemedicine group compared to the control group. On the other hand, ambulatory care costs in the telemedicine group increased two-fold compared to the control group. However, these costs only accounted for a 19% of the total costs. The reduction in costs observed in the telemedicine group was consistent across several subgroups of patients ( Figure 5(b) ).
Discussion
In our single-centre prospective randomized open blinded end-point study we found that follow-up of high-risk patients with CHF in the setting of HF programmes provides better results when planned care is provided using telemedicine. In particular, a telemedicine-based follow-up strategy was associated with a significant reduction in the number of non-fatal HF events (primary endpoint) and a reduced risk of HF and cardiovascular-related re-hospitalizations and associated number of days hospitalized. The benefits in the primary endpoint were consistent across all pre-specified subgroups. A non-significant trend toward a lower rate of all-cause and cardiovascular mortality was observed in the group that combined HFP and telemedicine. Furthermore, a significant reduction of direct costs associated with hospital health care was observed in the telemedicine group compared to the usual care group. These results are in line with the latest Cochrane review on this subject published in 2011 8 but are in contrast with the two largest published clinical trials. 5, 6 Several differences between our study and other studies that may help explain the difference in results. First, in the Telemedical Interventional Monitoring in Heart Failure study (TIM-HF) 6 patients had to be stable and optimally treated for a pre-specified period of time before qualifying for inclusion. This probably resulted in a selection of patients at lower risk of events and thus, with less room for improvement. Thus, we may speculate that selection during hospitalization may allow early intervention in the most vulnerable patients at increased risk of readmission. In these, early close monitoring may have high added value. Second, despite our expectation that patients were anticipating a certain concern about the use of new technologies, the adherence and satisfaction during follow-up was high. This was possibly due to the simplicity of use of the telemedicine system, the active engagement of the primary care team and patients throughout the monitoring process and the proactive interaction of the HF team with patients and primary care teams. In the design of our telemedicine solution we involved telecommunication engineers, clinicians and patients. The aim was to develop a user-friendly communication tool conceived for elderly patients accordingly to the needs of real-world HF patients. Our patients transferred their biometrics and symptom status daily through an automated system. Thus, the high level of acceptance and adherence observed in our cohort are in contrast with the findings of the Telemonitoring to Improve Heart Failure Outcomes Study (Tele-HF) 5 where a centralized interactive voice response system was used to perform telemonitoring and where the adherence and involvement of patients was very low.
Other studies such as the TENS-HMS 7 included patients at high risk of readmission and reported a high level of adherence and satisfaction of patients with the telemonitoring system. In this study, remote structured follow-up either alone or in combination with telemonitoring were superior to usual care. However, the combination of telemonitoring and structured telephone support did not improve the primary outcome compared to structured telephone support alone although there was a marginal benefit in other secondary end-points. In our study, HF nurses were allowed to adjust the dose of diuretics when the biometry suggested a HF decompensation. It is not clear whether a similar protocol was applied in the TENS-HMS. In fact, HF readmissions were higher in the combined group compared to structured telephone support alone although these hospitalizations tended to be shorter. The authors suggested that the early detection of new worsening in the patients allocated to home telemonitoring was translated into planned hospitalizations. The difference in the frequency of transmission of biometrics may also account for the differences observed in our study compared to the Finnish study. Thus, differences in the protocols of nurse interventions and a lower frequency of telemonitoring may account for the divergence between our results and those observed in the TENS-HMS 7 study and the Finnish 9 study respectively.
There are several reasons to support the role of remote monitoring in patients followed in a context of integrated management. Recent studies have shown that pulmonary and systemic congestion is associated to organ damage and that an early and more efficient decongestion may promote organ-protective effects particularly in the heart, kidney and liver. 17, 18 According to this hypothesis, each new episode of congestion may promote a recurrent organ damage that in turn would further compromise the cardiac, renal and hepatic function. Thus, early detection and treatment of a new congestive event could help preserve the function of these organs. 17, 18 This, in turn, may promote the prevention of future HF-related events or attenuate the severity of the new congestive episodes that could be easily managed with simple treatment intensifications. All these factors may prolong the periods of clinical stability required for treatment optimization. In favour of this hypothesis, we observed a reduction in the number of recurrent hospitalizations and a trend to a shorter hospital stay in the telemedicine group.
Our telemedicine service was deployed within a comprehensive, multidisciplinary, nurse-led, integrated hospital-primary care HF management programme. 2 We embedded our telemedicine service in our integrated health care area to complement the existing local clinical pathways and protocols in coordination with all the health care teams involved in the care of these patients, particularly with the primary care teams. Thus, our hypothesis is that the successful implementation of these systems requires a reorganization of health care at local level. 2, 3 The patient's interface of our telemedicine service incorporated elements such as feedback on biometrics and educational videos aimed to enhance self-efficacy and reassurance. From the perspective of patients and caregivers, these elements along with the support from the nurses may contribute to smooth the transition between hospitalization and the post-discharge period. 8 These models of remote care have many advantages in the current health care context of aging and multiple comorbidities 19 allowing the possibility of a high standard care to patients who are often expelled from specialized care. 8 Interestingly, in our study we have shown that the efficiency of telemedicine was independent of educational level, presence of HFpEF or HFrEF, severity of HF and the presence of depressive symptoms or frailty.
Study limitations
This study has the typical limitations of an open-label trial where allocation to an intervention could not be masked. Our study was limited at six months. The optimal duration and the persistence of the observed benefit in such interventions are currently unknown. The telemedicine service was implemented within a comprehensive HF programme. This means that the scalability and generalizability of the results is feasible if this telemedicine system is embedded in a well-organized process. An additional limitation of single centre studies evaluating openlabel interventions is that the motivation of the team may be at least partially responsible for achieving positive results that in turn may not be scalable to other centres or areas. To overcome this limitation, the two modalities of intervention performed in our study were delivered by two independent teams. Therefore, we expected a similar degree of motivation and engagement in both intervention teams.
Conclusions
In this single-centre prospective randomized open-label end-point study we have shown that the addition of telemedicine to an existing comprehensive HF programme improves outcomes. Delivering health care to high-risk CHF patients with the combination of remote daily monitoring of signs and symptoms of HF (telemonitoring) and structured follow-up using videoconference (teleintervention) reduced the risk of non-fatal HF events and the risk of HF and cardiovascular-related readmissions compared to the strategy of providing structured follow-up on the basis of face-to-face encounters (usual care in a HF programme). These benefits were seen across pre-specified subgroups of patients and were accompanied by reduction in hospital costs and improvement in patient-centred outcomes. Further research is warranted to evaluate generalization of the results, to explore the impact in mortality and to ascertain the optimal duration of this type of intervention.
